ASX News in English<p>Avecho Biotechnology wins US$3M deal with Sandoz for exclusive CBD insomnia... - published 27 Mar 2025 <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <br><a href="https://grafa.com/news/health-avecho-biotechnology-wins-us-3m-deal-with-sandoz-for-exclusive-cbd-insomnia-treatment-408231?utm_source=asx_news_en&utm_medium=mastodon&utm_campaign=408231" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-avecho-b</span><span class="invisible">iotechnology-wins-us-3m-deal-with-sandoz-for-exclusive-cbd-insomnia-treatment-408231?utm_source=asx_news_en&utm_medium=mastodon&utm_campaign=408231</span></a></p>
Recent searches
No recent searches
Search options
Only available when logged in.
c.im is one of the many independent Mastodon servers you can use to participate in the fediverse.
C.IM is a general, mainly English-speaking Mastodon instance.
Administered by:
Server stats:
2.9Kactive users
c.im: About · Status · Profiles directory · Privacy policy
Mastodon: About · Get the app · Keyboard shortcuts · View source code · v4.3.6
#clinicaltrials
22 posts · 16 participants · 0 posts today
asx_news_de<p>Avecho Biotechnology schließt einen Vertrag über 3 Millionen US-Dollar mit ... - published 27 Mar 2025 <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <br><a href="https://grafa.com/news/de-health-avecho-biotechnology-wins-us-3m-deal-with-sandoz-for-exclusive-cbd-insomnia-treatment-408263?utm_source=asx_news_de&utm_medium=mastodon&utm_campaign=408263" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/de-health-avech</span><span class="invisible">o-biotechnology-wins-us-3m-deal-with-sandoz-for-exclusive-cbd-insomnia-treatment-408263?utm_source=asx_news_de&utm_medium=mastodon&utm_campaign=408263</span></a></p>
US News in English<p>Septerna unveils corporate overview and 2024 financial results - published 27 Mar 2025 <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <a href="https://mastodon-grafa.social/tags/BioTech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BioTech</span></a> <a href="https://mastodon-grafa.social/tags/Grafa" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Grafa</span></a> <br><a href="https://grafa.com/news/health-septerna-unveils-corporate-overview-and-2024-financial-results-407988?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=407988" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-septerna</span><span class="invisible">-unveils-corporate-overview-and-2024-financial-results-407988?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=407988</span></a></p>
US News in English<p>Alterity Therapeutics completes Phase 2 open-label study for advanced MSA t... - published 27 Mar 2025 <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <a href="https://mastodon-grafa.social/tags/BioTech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BioTech</span></a> <a href="https://mastodon-grafa.social/tags/Grafa" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Grafa</span></a> <br><a href="https://grafa.com/news/health-alterity-therapeutics-completes-phase-2-open-label-study-for-advanced-msa-treatment-407896?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=407896" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-alterity</span><span class="invisible">-therapeutics-completes-phase-2-open-label-study-for-advanced-msa-treatment-407896?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=407896</span></a></p>
ASX Mkt. Sensitive<p>Race Oncology ( <a href="https://mastodon-grafa.social/tags/RAC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>RAC</span></a> ) has released " Race Initiates First AU Site for Phase 1 Solid Tumour Trial " on Thu 27 Mar at 15:53 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <br><a href="https://grafa.com/asset/race-oncology-ltd-3890-rac.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=rac.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/race-oncology-</span><span class="invisible">ltd-3890-rac.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=rac.asx</span></a></p>
ASX Mkt. Sensitive<p>Actinogen Medical ( <a href="https://mastodon-grafa.social/tags/ACW" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ACW</span></a> ) has released " ACW conducts Type C meeting with FDA regarding depression " on Thu 27 Mar at 11:58 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <br><a href="https://grafa.com/asset/actinogen-medical-ltd-5264-acw.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=acw.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/actinogen-medi</span><span class="invisible">cal-ltd-5264-acw.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=acw.asx</span></a></p>
ASX Mkt. Sensitive<p>Alterity Therapeutics ( <a href="https://mastodon-grafa.social/tags/ATH" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ATH</span></a> ) has released " Alterity Completes Last Patient Visit in Open-Label Trial " on Thu 27 Mar at 10:41 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <br><a href="https://grafa.com/asset/alterity-therapeutics-ltd-641-ath.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=ath.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/alterity-thera</span><span class="invisible">peutics-ltd-641-ath.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=ath.asx</span></a></p>
asx_news_de<p>Neuren Pharmaceuticals treibt NNZ-2591 für die Behandlung von Hirnverletzun... - published 26 Mar 2025 <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/News" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>News</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <a href="https://mastodon-grafa.social/tags/Business" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Business</span></a> <br><a href="https://grafa.com/news/de-business-news-neuren-pharmaceuticals-advances-nnz-2591-for-newborn-brain-injury-treatment-407219?utm_source=asx_news_de&utm_medium=mastodon&utm_campaign=407219" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/de-business-new</span><span class="invisible">s-neuren-pharmaceuticals-advances-nnz-2591-for-newborn-brain-injury-treatment-407219?utm_source=asx_news_de&utm_medium=mastodon&utm_campaign=407219</span></a></p>
ASX News in English<p>Neuren Pharmaceuticals advances NNZ-2591 for newborn brain injury treatment - published 26 Mar 2025 <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/News" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>News</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <a href="https://mastodon-grafa.social/tags/Business" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Business</span></a> <br><a href="https://grafa.com/news/business-news-neuren-pharmaceuticals-advances-nnz-2591-for-newborn-brain-injury-treatment-407148?utm_source=asx_news_en&utm_medium=mastodon&utm_campaign=407148" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/business-news-n</span><span class="invisible">euren-pharmaceuticals-advances-nnz-2591-for-newborn-brain-injury-treatment-407148?utm_source=asx_news_en&utm_medium=mastodon&utm_campaign=407148</span></a></p>
ASX Mkt. Sensitive<p>Clinuvel Pharmaceuticals ( <a href="https://mastodon-grafa.social/tags/CUV" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>CUV</span></a> ) has released " CLINUVEL renews share buy-back program " on Thu 27 Mar at 09:03 AEST <a href="https://mastodon-grafa.social/tags/tax" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>tax</span></a> <a href="https://mastodon-grafa.social/tags/government" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>government</span></a> <a href="https://mastodon-grafa.social/tags/China" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>China</span></a> <a href="https://mastodon-grafa.social/tags/trading" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>trading</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <br><a href="https://grafa.com/asset/clinuvel-pharmaceuticals-ltd-6512-cuv.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=cuv.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/clinuvel-pharm</span><span class="invisible">aceuticals-ltd-6512-cuv.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=cuv.asx</span></a></p>
US News in English<p>Mereo BioPharma reports 2024 financial results and advances rare disease pi... - published 26 Mar 2025 <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <a href="https://mastodon-grafa.social/tags/Grafa" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Grafa</span></a> <a href="https://mastodon-grafa.social/tags/DeFi" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>DeFi</span></a> <br><a href="https://grafa.com/news/health-mereo-biopharma-reports-2024-financial-results-and-advances-rare-disease-pipeline-406834?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=406834" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-mereo-bi</span><span class="invisible">opharma-reports-2024-financial-results-and-advances-rare-disease-pipeline-406834?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=406834</span></a></p>
IQWiG<p>What to do if <a href="https://wisskomm.social/tags/PubMed" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>PubMed</span></a> goes down the drain </p><p>The news from the US is unsettling, not least for medical information specialists. Siw Waffenschmidt, Head of our Department of Information Management, asks <span class="h-card" translate="no"><a href="https://mastodon.online/@hildabast" class="u-url mention" rel="nofollow noopener noreferrer" target="_blank">@<span>hildabast</span></a></span>, author of the blog 'Absolutely Maybe' and former NIH employee, for an assessment of the situation regarding PubMed and <a href="https://wisskomm.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a>.gov. How can all of us prepare for possible PubMed downtimes or deficiencies?</p><p><a href="https://youtu.be/fn2paCE6Zco?si=atNcEhzfP3Ptbuuk" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">youtu.be/fn2paCE6Zco?si=atNcEh</span><span class="invisible">zfP3Ptbuuk</span></a></p>
ASX Mkt. Sensitive<p>4Dmedical ( <a href="https://mastodon-grafa.social/tags/4DX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>4DX</span></a> ) has released " Cost reduction program delivers $6.5m in annualised savings " on Wed 26 Mar at 09:58 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/tax" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>tax</span></a> <a href="https://mastodon-grafa.social/tags/ArtificialIntelligence" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ArtificialIntelligence</span></a> <a href="https://mastodon-grafa.social/tags/NYSE" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NYSE</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <br><a href="https://grafa.com/asset/4dmedical-ltd-5186-4dx.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=4dx.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/4dmedical-ltd-</span><span class="invisible">5186-4dx.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=4dx.asx</span></a></p>
ASX Mkt. Sensitive<p>Clinuvel Pharmaceuticals ( <a href="https://mastodon-grafa.social/tags/CUV" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>CUV</span></a> ) has released " Positive preliminary results for PRENUMBRA Instant in stroke " on Wed 26 Mar at 09:15 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/tax" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>tax</span></a> <a href="https://mastodon-grafa.social/tags/government" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>government</span></a> <a href="https://mastodon-grafa.social/tags/China" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>China</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <br><a href="https://grafa.com/asset/clinuvel-pharmaceuticals-ltd-6512-cuv.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=cuv.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/clinuvel-pharm</span><span class="invisible">aceuticals-ltd-6512-cuv.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=cuv.asx</span></a></p>
ASX Mkt. Sensitive<p>Orthocell ( <a href="https://mastodon-grafa.social/tags/OCC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OCC</span></a> ) has released " First Sales of Striate in Germany, Austria & Swiss Region " on Wed 26 Mar at 09:02 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <br><a href="https://grafa.com/asset/orthocell-ltd-177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/orthocell-ltd-</span><span class="invisible">177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx</span></a></p>
US News in English<p>Kezar Life Sciences reports positive results for zetomipzomib and 2024 fina... - published 25 Mar 2025 <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <br><a href="https://grafa.com/news/health-kezar-life-sciences-reports-positive-results-for-zetomipzomib-and-2024-financials-405779?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=405779" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-kezar-li</span><span class="invisible">fe-sciences-reports-positive-results-for-zetomipzomib-and-2024-financials-405779?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=405779</span></a></p>
Europe Says<p><a href="https://www.europesays.com/1940136/" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="">europesays.com/1940136/</span><span class="invisible"></span></a> What is glioblastoma, the aggressive brain cancer that killed former US Rep. Mia Love? <a href="https://pubeurope.com/tags/america" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>america</span></a> <a href="https://pubeurope.com/tags/BarackObama" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BarackObama</span></a> <a href="https://pubeurope.com/tags/BeauBiden" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BeauBiden</span></a> <a href="https://pubeurope.com/tags/BrainCancer" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BrainCancer</span></a> <a href="https://pubeurope.com/tags/cancer" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>cancer</span></a> <a href="https://pubeurope.com/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://pubeurope.com/tags/DonaldTrump" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>DonaldTrump</span></a> <a href="https://pubeurope.com/tags/GeneralNews" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>GeneralNews</span></a> <a href="https://pubeurope.com/tags/health" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>health</span></a> <a href="https://pubeurope.com/tags/JoeBiden" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>JoeBiden</span></a> <a href="https://pubeurope.com/tags/JohnMcCain" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>JohnMcCain</span></a> <a href="https://pubeurope.com/tags/MiaLove" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MiaLove</span></a> <a href="https://pubeurope.com/tags/MiaLoveWhat" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MiaLoveWhat</span></a> <a href="https://pubeurope.com/tags/NCStateWire" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NCStateWire</span></a> <a href="https://pubeurope.com/tags/Politics" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Politics</span></a> <a href="https://pubeurope.com/tags/RobertTisch" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>RobertTisch</span></a> <a href="https://pubeurope.com/tags/SaltLakeCity" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>SaltLakeCity</span></a> <a href="https://pubeurope.com/tags/U" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>U</span></a>.S.News <a href="https://pubeurope.com/tags/UnitedStates" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStates</span></a> <a href="https://pubeurope.com/tags/UnitedStatesHouseOfRepresentatives" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStatesHouseOfRepresentatives</span></a> <a href="https://pubeurope.com/tags/UnitedStatesOfAmerica" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStatesOfAmerica</span></a> <a href="https://pubeurope.com/tags/US" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>US</span></a> <a href="https://pubeurope.com/tags/USNews" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>USNews</span></a> <a href="https://pubeurope.com/tags/USTopics" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>USTopics</span></a> <a href="https://pubeurope.com/tags/USA" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>USA</span></a> <a href="https://pubeurope.com/tags/USANews" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>USANews</span></a> <a href="https://pubeurope.com/tags/UTStateWire" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UTStateWire</span></a> <a href="https://pubeurope.com/tags/Utah" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Utah</span></a> <a href="https://pubeurope.com/tags/YasmeenRauf" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>YasmeenRauf</span></a></p>
ASX Mkt. Sensitive<p>EBR Systems ( <a href="https://mastodon-grafa.social/tags/EBR" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>EBR</span></a> ) has released " 2024 Activity Report and Form 10-K submission " on Tue 25 Mar at 08:48 AEST <a href="https://mastodon-grafa.social/tags/NYSE" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NYSE</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <br><a href="https://grafa.com/asset/ebr-systems-inc-cdr-6751-ebr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=ebr.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/ebr-systems-in</span><span class="invisible">c-cdr-6751-ebr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=ebr.asx</span></a></p>
Hacker News<p>Eli Lilly will soon release key data on its weight loss pill orforglipron</p><p><a href="https://www.cnbc.com/2025/03/24/eli-lilly-to-release-weight-loss-pill-orforglipron-trial-data-.html" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="ellipsis">cnbc.com/2025/03/24/eli-lilly-</span><span class="invisible">to-release-weight-loss-pill-orforglipron-trial-data-.html</span></a></p><p><a href="https://mastodon.social/tags/HackerNews" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>HackerNews</span></a> <a href="https://mastodon.social/tags/EliLilly" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>EliLilly</span></a> <a href="https://mastodon.social/tags/Orforglipron" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Orforglipron</span></a> <a href="https://mastodon.social/tags/WeightLoss" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>WeightLoss</span></a> <a href="https://mastodon.social/tags/Pill" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Pill</span></a> <a href="https://mastodon.social/tags/HealthInnovation" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>HealthInnovation</span></a> <a href="https://mastodon.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a></p>
US News in English<p>UNITY Biotechnology announces positive Phase 2b trial results for UBX1325 i... - published 24 Mar 2025 <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <a href="https://mastodon-grafa.social/tags/BioTech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BioTech</span></a> <a href="https://mastodon-grafa.social/tags/Grafa" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Grafa</span></a> <a href="https://mastodon-grafa.social/tags/Technology" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Technology</span></a> <br><a href="https://grafa.com/news/health-unity-biotechnology-announces-positive-phase-2b-trial-results-for-ubx1325-in-diabetic-macular-edema-404715?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=404715" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-unity-bi</span><span class="invisible">otechnology-announces-positive-phase-2b-trial-results-for-ubx1325-in-diabetic-macular-edema-404715?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=404715</span></a></p>
ExploreLive feeds
Mastodon is the best way to keep up with what's happening.
Follow anyone across the fediverse and see it all in chronological order. No algorithms, ads, or clickbait in sight.
Create accountLoginDrag & drop to upload